Screener
United Therapeutics UTHR Net gains (losses) on investments
Net gains (losses) on investments at other companies
Other financials
Where this comes from
Reported directly by United Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss.
The source filing: United Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001082554-26-000027
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Depreciation and amortization | 46.8 | 40.9 |
| Share-based compensation expense | 77.3 | 69.6 |
| Impairment of property, plant, and equipment | — | 21.7 |
| Net unrealized losses on equity securities | 48.2 | 9.3 |
| Deferred income taxes | 51.6 | — |
| Other | 56.8 | 4.7 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 39.9 | (100.0) |
Item 1. Consolidated Financial Statements
FAQ
- What is United Therapeutics's net gains (losses) on investments?
- United Therapeutics (UTHR) reported net gains (losses) on investments of $13.4M in Q2 2026.
- What does net gains (losses) on investments mean?
- Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.
Ask your AI about United Therapeutics's net gains (losses) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude